LEXX

Lexaria Bioscience Corp

4.44

Nov 13 • 3:59 PM ET +0.26 (6.22%)

4.44

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology Canada Nano NASD

Peers: ORMP RANI ENTX LPCN MTVA GUTS ARTL NTRB IGC ALT

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	9.36M
Enterprise Value	5.44M
Income	-7.73M
Sales	0.19M
Book/sh	2.87
Cash/sh	1.72
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7
IPO	Oct 10, 2006

P/E	-
Forward P/E	-
PEG	-
P/S	49.25
P/B	1.55
P/C	2.59
P/FCF	-
EV/EBITDA	-
EV/Sales	28.62
Quick Ratio	10.60
Current Ratio	10.60
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-5.28
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	18.80% 14.16%
Sales past 3/5Y	40.34% 17.53%
EPS Y/Y TTM	46.85%
Sales Y/Y TTM	-68.50%
EPS Q/Q	61.24%
Sales Q/Q	-100.00%
Earnings	Jul 17
EPS/Sales Surpr.	-33.33% -

Insider Own	2.96%
Insider Trans	0.00%
Inst Own	5.22%
Inst Trans	0.25%
ROA	-134.21%
ROE	-150.28%
ROIC	-161.36%
Gross Margin	48.98%
Oper. Margin	-3862.94%
Profit Margin	-3985.58%
SMA20	20.44%
SMA50	16.24%
SMA200	-48.28%
Trades

Shs Outstand	2.11M
Shs Float	2.04M
Short Float	10.66%
Short Ratio	2.95
Short Interest	0.22M
52W High	21.60 -79.44%
52W Low	2.43 82.72%
Volatility	7.42% 12.32%
ATR (14)	0.48
RSI (14)	57.62
Beta	0.57
Rel Volume	0.12
Avg Volume	73.60K
Volume	9,028

Perf Week	-1.33%
Perf Month	48.49%
Perf Quarter	-56.98%
Perf Half Y	-50.02%
Perf YTD	-52.03%
Perf Year	-73.09%
Perf 3Y	-77.58%
Perf 5Y	-95.49%
Perf 10Y	-96.13%
Recom	1.00
Target Price	82.50
Prev Close	4.18
Price	4.44
Change %	6.22%

Nov-04-26 09:00AM	Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH (ACCESSWIRE)
Oct-28-26 09:10AM	Lexaria Celebrates its 70th Patent Award (ACCESSWIRE)
Oct-21-26 09:25AM	Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule (ACCESSWIRE) +6.42%
Oct-15-26 09:10AM	Lexaria Announces Results from Animal Study GLP-1-A26-1 (ACCESSWIRE) +6.03%
Oct-06-26 09:10AM	GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications (ACCESSWIRE) +16.97%
09:10AM	Loading…
Sep-17-26 09:10AM	Lexaria Updates Financial Position (ACCESSWIRE) +6.30%
Sep-09-26 04:15PM	Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds (ACCESSWIRE) -29.56% -38.64%
Sep-08-26 08:00AM	Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds (ACCESSWIRE) -33.78%
Sep-04-26 09:20AM	Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference (ACCESSWIRE) +14.85%
Sep-01-26 09:15AM	Lexaria Receives USD$2.6 Million Tax Rebate Payment (ACCESSWIRE) +10.59%
Aug-24-26 09:10AM	DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2 (ACCESSWIRE)
Aug-13-26 09:00AM	Lexaria Enters a Material Transfer Agreement With PegBio (ACCESSWIRE) +32.35%
Jul-30-26 11:00AM	Lexaria Announces Effective Date for Reverse Stock Split (ACCESSWIRE) -25.23%
Jul-06-26 09:10AM	Lexaria Updates Business Development (ACCESSWIRE)
Jun-25-26 09:10AM	Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule (ACCESSWIRE)
09:25AM	Loading…
Jun-23-26 09:25AM	Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule (ACCESSWIRE)
Jun-17-26 09:25AM	GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand (ACCESSWIRE)
Jun-09-26 09:25AM	Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway (ACCESSWIRE)
Jun-03-26 09:25AM	Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program (ACCESSWIRE)
May-19-26 09:15AM	Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 (ACCESSWIRE)
May-07-26 09:25AM	Lexaria Bioscience Releases Second Episode of Investor Video Series (ACCESSWIRE)
May-05-26 09:10AM	Lexaria Updates Progress on Human Study #7 (ACCESSWIRE)
May-01-26 09:25AM	Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications (ACCESSWIRE) +7.94%
Apr-29-26 09:10AM	Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended (ACCESSWIRE) -21.93%
Apr-23-26 09:05AM	Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs (ACCESSWIRE)
Apr-21-26 09:10AM	Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales (ACCESSWIRE)
Apr-15-26 09:10AM	Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property (ACCESSWIRE)
Apr-07-26 09:10AM	Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval (ACCESSWIRE) -6.60%
Apr-01-26 09:20AM	Lexaria to Begin New Human Clinical Study in GLP-1 (ACCESSWIRE) +11.04%
Mar-26-26 09:20AM	Lexaria's Robust Patent Portfolio Continues to Grow (ACCESSWIRE)
09:15AM	Loading…
Mar-24-26 09:15AM	Lexaria's Oral GLP-1 Drug Strategy Validated by Industry (ACCESSWIRE) +7.12%
Mar-04-26 09:25AM	Lexaria Announces New R&D Plans for 2026 (ACCESSWIRE) +5.04%
Feb-05-26 09:15AM	Lexaria Announces Positive Final Results From Human Pilot Study #5 (ACCESSWIRE) -8.66%
Jan-22-26 09:20AM	Lexaria Awarded Six Additional Patents (ACCESSWIRE)
Jan-12-26 09:10AM	Lexaria Releases Annual Letter from the CEO (ACCESSWIRE)
Dec-31-25 09:25AM	Lexaria releases additional results from Phase 1b study GLP-1-H24-4 (TipRanks) +13.46%
Dec-30-25 09:20AM	Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 (ACCESSWIRE)
Dec-23-25 09:29AM	Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 (ACCESSWIRE) -8.01%
Dec-16-25 04:00PM	Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -5.62% -18.86%
Dec-15-25 08:00AM	Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -33.58%
Nov-12-25 09:10AM	Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended (ACCESSWIRE)
Oct-09-25 09:20AM	Lexaria Bioscience Corp. Provides Strategic Update (ACCESSWIRE)
Sep-29-25 04:30PM	Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -6.40%
Sep-26-25 08:00AM	Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -31.37%
Sep-19-25 11:20AM	Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain (ACCESSWIRE)
Aug-27-25 09:20AM	Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference (ACCESSWIRE)
Aug-15-25 09:25AM	Lexaria Bioscience announces last patient, last visit in Phase 1b GLP-1 study (TipRanks)
Aug-14-25 09:20AM	Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone (ACCESSWIRE)
Aug-06-25 09:20AM	GLP-1 "Arms Race" Broadens to Include Dozens of Companies (ACCESSWIRE)
Jul-28-25 09:25AM	Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study (ACCESSWIRE) -8.49%
Jul-23-25 09:25AM	Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry (ACCESSWIRE) +6.19%
Jun-23-25 09:15AM	Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide (ACCESSWIRE)
Jun-12-25 09:15AM	Lexaria Bioscience announces completion of GLP-1-H25-5 study (TipRanks)
Jun-11-25 09:05AM	Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule (ACCESSWIRE)
Jun-05-25 09:20AM	Lexaria Attending BIO International Convention (ACCESSWIRE)
May-12-25 09:00AM	Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company (ACCESSWIRE)
Apr-28-25 04:15PM	Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock (ACCESSWIRE) -9.63%
Apr-25-25 08:00AM	Lexaria Announces $2 Million Registered Direct Offering of Common Stock (ACCESSWIRE) -20.12%
Apr-23-25 09:10AM	Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology (ACCESSWIRE) +8.90%
Apr-03-25 09:10AM	Lexaria Updates its Ongoing Human Study GLP-1-H24-4 (ACCESSWIRE) -8.38%
Mar-18-25 09:15AM	Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R) (ACCESSWIRE) -5.25%
Feb-27-25 08:00AM	The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience (ACCESSWIRE)
Feb-24-25 08:00AM	Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm (ACCESSWIRE) +5.52%
Feb-20-25 08:00AM	Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide (ACCESSWIRE) -10.06%
Feb-11-25 08:00AM	Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy (ACCESSWIRE) -5.29%
Feb-06-25 09:40AM	Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway (ACCESSWIRE)
Feb-05-25 09:10AM	Lexaria Updates its Ongoing Human Study GLP-1-H24-4 (ACCESSWIRE) +5.08%
Jan-30-25 09:15AM	Lexaria Releases Annual Letter from the CEO (ACCESSWIRE)
Jan-15-25 09:20AM	Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval (ACCESSWIRE)
Jan-14-25 09:10AM	Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R) (ACCESSWIRE) -6.31%
Dec-19-24 09:05AM	Lexaria's Registered GLP-1 Study #4 Begins Dosing (ACCESSWIRE)
Dec-18-24 09:25AM	Lexaria Forms New Scientific Advisory Board (ACCESSWIRE)
Dec-17-24 09:10AM	Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience (ACCESSWIRE)
Dec-10-24 09:43AM	Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide (TipRanks)
Dec-09-24 09:10AM	Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 (ACCESSWIRE)
Nov-30-24 11:00AM	BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, and Surge Battery Metals (Newsfile)
11:00AM	BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals (Newsfile)
Nov-26-24 09:20AM	Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs (ACCESSWIRE)
Nov-25-24 09:00AM	Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled (ACCESSWIRE)
Nov-20-24 09:05AM	ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study (ACCESSWIRE)
Nov-14-24 09:10AM	Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study (ACCESSWIRE) -6.19%
Nov-13-24 09:20AM	Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss (ACCESSWIRE)
Nov-07-24 09:15AM	Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments (ACCESSWIRE) +5.94%
Oct-24-24 09:10AM	Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Oct-22-24 09:20AM	Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Oct-16-24 04:00PM	Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE)
Oct-15-24 08:25AM	Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -6.21%
Oct-09-24 09:05AM	Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing (ACCESSWIRE)
Oct-08-24 09:20AM	Lexaria Updates Current GLP-1 Market (ACCESSWIRE)
Oct-01-24 09:25AM	Lexaria Appoints Michael Shankman as Chief Financial Officer (ACCESSWIRE)
Sep-27-24 09:20AM	Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 (ACCESSWIRE)
Sep-05-24 10:00AM	Lexaria Releases Strategic Letter from the Outgoing CEO (ACCESSWIRE)
09:00AM	Lexaria Welcomes Industry Veteran as New CEO (ACCESSWIRE)
Sep-03-24 08:30AM	Lexaria Enters a Material Transfer Agreement for DehydraTECH Research (ACCESSWIRE) -6.65%
Aug-29-24 09:25AM	Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules (ACCESSWIRE) +10.62%
Aug-27-24 09:20AM	First Results from Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Aug-22-24 09:20AM	Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE) -7.90%
Aug-21-24 09:00AM	Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Aug-19-24 09:05AM	Positive Results from Lexaria's Molecular Characterization Study (ACCESSWIRE)
Jul-17-24 10:30AM	Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study (ACCESSWIRE)

Show Previous News

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. It operates through the IP licensing segment which generates revenue from customers by licensing its proprietary DehydraTECH technology. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

CEO & DirectorMr. Richard C. Christopher

Chairman of the Scientific Advisory BoardMr. John M. Docherty M.Sc.

Chief Financial OfficerMr. Michael Shankman CPA

Director of OperationsMs. Kristin Hamilton

Head of LegalMs. Vanessa Carle

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

LEXX

Lexaria Bioscience Corp

Upgrade your Finviz experience

All the Features.
Half the Price.